3M India Q1FY26 PAT rises 31% to ₹233 crore on ₹73 crore land sale gain
3M India's Q1FY26 results show a 31.2% surge in net profit to ₹233 crore, heavily influenced by a ₹73.13 crore one-time gain from a land sale. Operational metrics reveal mixed signals: while revenue grew 19% to ₹1,423 crore with double-digit gains across all segments, core profit before tax fell 4.3% due to rupee depreciation. EBITDA also dipped slightly by 2.7%. The company marked its fifth consecutive quarter of double-digit sales growth, demonstrating resilient demand despite macroeconomic currency pressures.

*this image is generated using AI for illustrative purposes only.
3M India reported a standalone net profit of ₹233.07 crore for the quarter ended June 30, 2026 (Q1FY26), a significant increase of 31.2% from ₹177.69 crore in the same period last year. This bottom-line expansion was primarily driven by an exceptional one-time gain of ₹73.13 crore from the sale of land located in Pimpri, Pune. On the top line, revenue from operations grew robustly by 19% to ₹1,423.21 crore, compared to ₹1,195.97 crore in Q1FY25. The company also announced its fifth consecutive quarter of double-digit year-on-year sales growth.
Q1FY26 financial performance
While the headline profit figures showed strong growth, operational profitability faced headwinds. Profit before tax (PBT) excluding exceptional items stood at ₹229.03 crore, down 4.3% from ₹239.40 crore in Q1FY25. Mr. Aseem Joshi, Managing Director, attributed this decline to the impact of Indian rupee depreciation. EBITDA also contracted slightly by 2.7% to ₹250 crore from ₹257 crore previously. Despite the operational pressure, all four business segments—Safety & Industrial, Transportation & Electronics, Health Care, and Consumer—registered revenue growth.
| Metric: | Q1FY26 | Q1FY25 | YoY Change |
|---|---|---|---|
| Revenue from operations: | ₹1,423.21 crore | ₹1,195.97 crore | +19.0% |
| EBITDA: | ₹250 crore | ₹257 crore | -2.7% |
| PBT (excl. exceptional): | ₹229.03 crore | ₹239.40 crore | -4.3% |
| PBT (incl. exceptional): | ₹302.16 crore | ₹239.40 crore | +26.2% |
| Net Profit (PAT): | ₹233.07 crore | ₹177.69 crore | +31.2% |
The Board of Directors approved the unaudited financial results at its meeting held on August 14, 2026. The results were reviewed by statutory auditors B S R & Co. LLP, which issued an unqualified review opinion.
Segment-wise performance
Broad-based growth was observed across all key segments. Health Care led the pack with a 23.5% revenue increase to ₹296.99 crore, followed by Safety & Industrial which grew 23.0% to ₹465.33 crore. Transportation & Electronics revenue rose 14.4% to ₹503.36 crore, while the Consumer segment saw a 13.4% jump to ₹147.96 crore.
In terms of segment results (profitability), Safety & Industrial contributed the highest at ₹69.82 crore, followed by Transportation & Electronics at ₹67.72 crore. Health Care and Consumer segments reported results of ₹58.92 crore and ₹23.13 crore, respectively.
What the Numbers Show
The divergence between top-line growth and core operating profit highlights the currency headwinds facing the company. While revenue expanded by approximately ₹227 crore (from ₹1,195.97 crore to ₹1,423.21 crore), core PBT before exceptional items actually declined by ₹10.37 crore. This suggests that input costs or forex losses outpaced pricing power or volume gains during the quarter. The headline PAT growth of 31.2% is therefore not reflective of operational leverage but is instead driven by the non-recurring ₹73.13 crore land sale gain, which constituted roughly 31% of the total reported net profit. Without this exceptional item, the underlying profitability would have contracted despite strong sales momentum.
Historical Stock Returns for 3M India
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.28% | -1.83% | -2.99% | +0.64% | +15.89% | +46.78% |
How will 3M India adjust its pricing strategy to offset the impact of Indian rupee depreciation on core operational profitability in upcoming quarters?
What specific hedging strategies is the company implementing to mitigate future foreign exchange risks given the recent decline in EBITDA and PBT?
Can the company sustain its streak of double-digit sales growth across all four segments, particularly in the competitive Safety & Industrial and Health Care sectors?


































